Role of NeuraceqTM (Florbetaben F18 Injection) PET in Young Athletes With and Without Persistent Cognitive Complaints Following Multiple Concussions: A Pilot Study
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Postconcussional syndrome
- Focus Diagnostic use; Therapeutic Use
Most Recent Events
- 26 Feb 2024 Status changed from active, no longer recruiting to completed.
- 05 Sep 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 16 Mar 2022 New trial record